Management of severe dabigatran-related hemorrhage: Case report, considerations for management, and recommendations

Canadian Journal of Hospital Pharmacy

Volumn 67, Issue 1, 2014, Pages 43-47

  Plener, Ian ^a   Sadry, Sharon ^a   Mozessohn, Lee ^b   Lee, Justin Y ^c   Man, Damen ^d   Shehata, Nadine ^a,b   Singh, Jeffrey M ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d Abbotsford Regional Hospital   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; ALFUZOSIN; AMOXICILLIN; CELECOXIB; CIPROFLOXACIN; COTRIMOXAZOLE; DABIGATRAN; DIGOXIN; FRESH FROZEN PLASMA; HYDROCHLOROTHIAZIDE; LEVOTHYROXINE; LISINOPRIL; NITROFURANTOIN; OCTREOTIDE; PANTOPRAZOLE; PROTHROMBIN COMPLEX; TOLTERODINE; VITAMIN K GROUP;

AGED; ANEMIA; ARTICLE; ATRIAL FIBRILLATION; BLOOD CLOTTING DISORDER; DISEASE SEVERITY; EMERGENCY WARD; ERYTHROCYTE CONCENTRATE; FATIGUE; GASTROINTESTINAL HEMORRHAGE; HEMATEMESIS; HEMODIALYSIS PATIENT; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MELENA; RESUSCITATION; URINARY TRACT INFECTION; VERY ELDERLY;

EID: 84928655902     PISSN: 00084123     EISSN: 19202903     Source Type: Journal    
DOI: 10.4212/cjhp.v67i1.1322     Document Type: Article

References (23)

1. Ezekowitz MD, Wallendr I., Connolly SJ, Parekh A, Chernick M.R., Pogue J., et al.; RE-LY Steering Committee and Investigators. Dabigatran and warfarin in vitamin K antagonist-naive and - experienced cohorts with atrial fibrillation. Circulation. 2010; 122(22):2246-53.
2. Harper P, Young L, Mcrriman E. Bleeding risk with dabigatran in the frail elderly. N Engl J Med. 2012; 366(9):864-6.
3. Stangier J, Clemens A. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb Hernost. 2009; 15 Suppl 1:9S-16S.
4. Stangier J, Rathgen K, Stähle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet. 2010; 49(4):259-68.
5. Stangier J, Stähle H, Rathgen K., Futhr R. Pharmacokinetics and pharmacodynamics of the direct oral thrombin Inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet. 2008;47(1):47-59.
6. PRADAX™ (dabigatran etexilate) gains approval in Canada for stroke prevention in atrial fibrillation. Ingelheim (Germany): Bochringer Ingelheim Corporate Headquarters; 2010.
7. PRADAX [product monograph]. Burlington (ON): Bochringer Ingelheim Canada Ltd; 2012. 57 p.
8. Van Ryn J., Stangier J, Haertter S., Liesenfeld KH, Wienen W, Feuring M, et al Dabigatran etexilate - a novel, reversible, oral direcr thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulanr activity. Thromb Haemost. 2010; 103(6):1116-27.
9. Van Ryn J., Sieger P, Kink-Eiband M, Gansser D., Clemens A. Adsorption of dabigatran etexilate in water or dabigatran in pooled human plasma by activated charcoal in vitro [abstract]. Blood. 2009:114(22): 1065.
10. Hankey GJ, Eikelboom JW Dabigatran etexilate: a new oral thrombin inhibitor. Circulation. 2011; 123(13):1436-50.
11. Warkentin TE, Margetts P, Connolly SJ, Lamy A, Ricci C, Eikelboom JW. Recombinant factor VIIa (rFVlIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. Blood. 2012; 119(9): 2172-4.
12. Schulman S, Crowther MA. How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch. Blood. 2012; 119(13):3016-23.
13. Kaatz S, Kouides PA, Garcia DA, Spyropolous AC, Crowther M, Douketis JD, et al. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol. 2012; 87 Suppl 1:S141-5.
14. Crowther MA, Warkentin TE. Managing bleeding in anticoagulated patients with a focus on novel therapeutic agents. J Thromb Haemost. 2009; 7 Suppl 1:107-10.
15. Zhou W, Schwarting S, Manes S., Liesz A, Middelhoff M, Zorn M., et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke. 2011; 42(12):3594-9.
16. Levi M, Levy JH, Andersen H.F., Truloff D. Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med. 2010; 363(19): 1791-800.
17. Herenberg ES, Kamphuisen PW, Sijpkens M.K., Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011; 124(14):1573-9.
18. Van Ryn J., Ruehl D, Priepke H., Wienen W. Reversibility of the anticoagulant effect of high doses of the direct thrombin inhibitor dabigatran, by recombinant factor VIIa or activated prothrombin complex concentrate [abstract 0370]. Haematologica. 2008; 93 Suppl 1:148.
19. Marlu R, Hodaj E, Paris A., Albaladejo P, Crackowski JL, Pernod G. Effect or non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost. 2012; 108(2):217-24.
20. Haertter S, Tremmel M, Nehmiz G., Liesenfeld K, Moschetti V, Peters H., et al. Investigation of the elimination of dabigatran by haemodialysis in patients with end stage renal disease (ESRD) [abstract PI-68]. Clin Pharmacol Ther. 2012; 91 Suppl 1:S32.
21. Cano EL, Miyares MA. Clinical challenges in a patient with dahigatraninduced fatal hemorrhage. Am J Geriatr Pharmacother. 2012; 10(2):160-3.
22. van Ryn J., Neubauer M, Flieg R., Krause B, Storr M, Hauel N., et al. Successful removal of dabigatran in flowing blood with an activated charcoal hemoperfusion column in an in vitro test system [abstract]. Pathophysiol Haemost Thromb. 2010; 37 Suppl 1:A94.
23. Cushman M, Lim W, Zakai N. 2011 clinical practice guide on anticoagulant dosing and management of anticoagulant-associated bleeding complications in adults. Washington (DC): American Society of Hematology; 2011.